Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
Erasca, Inc. (NASDAQ:ERAS) has a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $22.09. The company's stock recently opened at $14.74, and institutional investors own a significant portion of its shares. Erasca is a clinical-stage biopharmaceutical company developing precision cancer medicines.
Erasca faces claims. JPMorgan targets Erasca stock at USD 33.00
Erasca, Inc. is facing securities claims related to disclosures for its drug candidate ERAS-0015, with allegations of inadequate explanation regarding intellectual-property risks compared to a competitor's drug. Despite these legal concerns and a significant Q2 2026 GAAP net loss of USD 44.08 million, JPMorgan maintained a USD 33.00 price target for the stock. The company, a clinical-stage biotechnology developer, continues to focus on its pipeline for RAS/MAPK pathway cancers while navigating legal scrutiny and clinical development challenges.
Erasca stock reports a second quarter loss after August results
Erasca (ERAS) reported a second-quarter loss of $0.14 per share, missing consensus estimates by $0.03. Despite the loss and negative operating cash flow, analysts maintain a "Moderate Buy" consensus with an average price target of $22.09, reflecting optimism about the company's clinical pipeline, especially after ERAS-0015 received FDA Fast Track Designation. Erasca recently conducted an upsized stock offering to fund research and development, and its next earnings date is set for November 11, 2026.
Erasca stock gains 4.12 percent ahead of trial data
Erasca stock rose 4.12 percent to USD 14.52 on September 24, 2026, ahead of scheduled updated ERAS-0015 trial data presentation in November. The company will present monotherapy data from its Phase 1 AURORAS-1 trial and nonclinical combination data for ERAS-0015 and ERAS-4001. Despite a recent quarterly loss exceeding consensus, the stock's daily gain positions the November update as a key milestone.
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (ERAS) on behalf of investors who purchased securities before January 14, 2025, and still hold them. The investigation focuses on possible corporate wrongdoing by Erasca and its officers/directors. The law firm encourages affected investors to contact them to assist in the investigation.
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (NASDAQ: ERAS). The investigation aims to determine if the Company's leadership fulfilled its obligations to shareholders and whether legal remedies are available. Shareholders who owned Erasca shares before January 14, 2025, are encouraged to contact the firm for a confidential consultation regarding their legal rights.
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by the directors and officers of Erasca, Inc. (NASDAQ: ERAS). The firm is seeking to determine if the company's leadership fulfilled its obligations to shareholders, particularly those who purchased shares before January 14, 2025. Shareholders are encouraged to contact Bernstein Liebhard LLP to discuss their legal rights.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Erasca, Inc. (NASDAQ:ERAS) and its officers/directors. The firm is encouraging Erasca stockholders who purchased securities prior to January 14, 2025, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for such class action and shareholder derivative suits.
ERAS 8-K Filings - Erasca, Inc. SEC 8-K
This article provides a comprehensive list of Erasca, Inc. (ERAS) 8-K filings with the SEC over the last 24 months, detailing material events between quarterly reports. Each entry includes a summary of the filing, covering topics such as FDA Fast Track Designations for cancer drugs, financial results including Q2 loss and cash raises, executive appointments, public stock offerings, safety data from clinical trials, and annual meeting results. The information is presented in reverse chronological order, with the newest filings appearing first.
Erasca, Inc. (NASDAQ: ERAS) foundation plans another ERAS stock sale
The Erasca Foundation has filed a Form 144 notice to sell 8,333 shares of Erasca, Inc. (ERAS) common stock, valued at approximately $133,093.91. This filing follows previous sales by the Foundation in June, July, and August 2026, and indicates the shares were originally acquired via a donation from Erasca, Inc. on July 20, 2021. The planned sale is set for September 15, 2026, through Merrill Lynch.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) for alleged corporate wrongdoing. The firm encourages Erasca shareholders who purchased securities before January 14, 2025, and still hold them, to contact them to assist with the investigation. This investigation operates on a contingency fee basis, meaning the firm only seeks reimbursement for expenses and fees if successful.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (ERAS) on behalf of investors who purchased securities prior to January 14, 2025, and continue to hold them. The investigation focuses on possible corporate wrongdoing by Erasca's officers and/or directors. The firm encourages affected investors to connect with them for more information and assistance.
Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2026.
Certain common stock of Erasca, Inc. are subject to a lock-up agreement that ends on September 12, 2026. This lock-up period, from July 13, 2026, to September 12, 2026, restricts directors, executive officers, and certain securityholders from selling or transferring their common stock without prior written consent from J.P. Morgan Securities LLC. The agreement aims to prevent market instability after an offering.
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca, Inc. will present updated monotherapy clinical data for ERAS-0015 and nonclinical combination data for ERAS-0015 and ERAS-4001 at the 38th EORTC-NCI-AACR Symposium. The presentations will highlight expanded results from the AURORAS-1 Phase 1 trial for ERAS-0015 and demonstrate synergy in KRAS G12X-driven models for the combination therapy. These findings underscore the potential of Erasca's therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts
Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $22.09, which is above its recent opening price of $16.19. Despite missing quarterly EPS estimates, institutional investors hold a significant 67.78% stake, and several major funds have increased their positions. The company is a clinical-stage biopharmaceutical firm focused on developing precision medicines for cancer.
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) on behalf of investors who purchased securities before January 14, 2025, and still hold them. The investigation focuses on whether Erasca and its officers engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to assist with the derivative lawsuit without any upfront cost.
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against its officers and directors for alleged breaches of fiduciary duty. Shareholders who held Erasca shares continuously prior to January 14, 2025, are encouraged to contact the firm regarding corporate governance reforms. The investigation stems from allegations in a previously filed securities complaint, including a patent infringement claim by Revolution Medicines and concerns about Erasca's disclosure of clinical data for ERAS-0015.
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Erasca, Inc. (ERAS) securities who bought prior to January 14, 2025. The investigation focuses on whether Erasca and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation at no cost.
BofA Securities Maintains Erasca(ERAS.US) With Hold Rating, Maintains Target Price $20
BofA Securities has reiterated its Hold rating on Erasca (ERAS.US) and maintained its price target of $20. This indicates a continued neutral outlook on the company's stock performance by the financial institution.
Erasca Receives FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Metastatic Pancreatic Cancer
Erasca, Inc. has received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for treating metastatic pancreatic adenocarcinoma. This designation highlights the urgent need for new therapies in this difficult-to-treat cancer. Early clinical trials show encouraging activity for ERAS-0015, particularly in KRAS G12X pancreatic cancer, with plans for Phase 3 studies underway.
FDA fast tracks Erasca’s pan-RAS molecular glue after early pancreatic cancer responses
The FDA has granted Fast Track Designation to Erasca's ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic adenocarcinoma. This designation follows promising Phase I data showing a 57% unconfirmed eight-week objective response rate in pancreatic cancer patients. The company plans to leverage this designation for further discussions with the FDA regarding a Phase III trial in pancreatic cancer and two additional registration-enabling trials in lung cancer, despite ongoing patent infringement and trade secret misappropriation claims.
Erasca receives FDA fast track status for pancreatic cancer drug By Investing.com
Erasca Inc. announced that the FDA has granted Fast Track Designation to its drug ERAS-0015 for metastatic pancreatic adenocarcinoma. This designation aims to expedite the development and review of therapies for serious conditions with unmet medical needs. Preliminary data from the AURORAS-1 Phase 1 trial showed a 57% overall response rate in patients with KRAS G12X pancreatic ductal adenocarcinoma treated with ERAS-0015 monotherapy.
Erasca receives FDA fast track status for pancreatic cancer drug
Erasca Inc. (NASDAQ:ERAS) has been granted Fast Track Designation by the U.S. FDA for its drug ERAS-0015, intended for metastatic pancreatic adenocarcinoma. This designation aims to accelerate the development and review of the oral pan-RAS molecular glue, which has shown promising preliminary results in Phase 1 trials with a 57% overall response rate in KRAS G12X pancreatic cancer patients. Erasca plans several registration-enabling trials for pancreatic and lung cancers.
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Erasca, Inc. has received FDA Fast Track Designation for its pan-RAS molecular glue ERAS-0015 for treating metastatic pancreatic adenocarcinoma. This designation aims to expedite development and review of the therapy, given the urgent need for new treatments. The company plans three potentially registration-enabling trials for ERAS-0015 in pancreatic and lung cancers, following encouraging Phase 1 data.
Erasca reports 57% preliminary response in patients with later-line KRAS G12X pancreatic cancer
Erasca has received FDA Fast Track Designation for its oral pan-RAS molecular glue ERAS-0015 to treat metastatic pancreatic adenocarcinoma. This designation follows promising preliminary Phase 1 data from the AURORAS-1 trial, which showed a 57% objective response rate in patients with later-line KRAS G12X pancreatic cancer. The company plans three potentially registration-enabling trials and expects further data readouts in the first half of 2027.
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Erasca made false or misleading statements regarding its ERAS-0015 product, specifically concerning preclinical data comparisons and potential patent infringement, which led to significant stock price declines. Investors who suffered substantial losses are encouraged to contact Robbins Geller to participate in the lawsuit.
Erasca | 10-Q: Q2 2026 Earnings Report
This document is Erasca's 10-Q filing for the second quarter of 2026. It contains the company's interim financial statements and provides a comprehensive overview of its financial performance and condition during that period.
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS
E Fund Management Co. Ltd. has acquired a new stake worth $4.86 million in Erasca, Inc., purchasing 265,381 shares. Institutional investors now collectively own 67.78% of Erasca. The company holds a "Moderate Buy" consensus rating from analysts, despite reporting a quarterly loss of $0.14 per share, missing estimates.
Law firm probes Erasca directors for possible breaches of fiduciary duty to shareholders.
Bernstein Liebhard LLP is investigating Erasca, Inc. directors and officers for potential breaches of fiduciary duty to shareholders. The probe aims to determine if their actions align with shareholders' best interests and if legal recourse is necessary. Shareholders who purchased Erasca shares before January 14, 2025, are encouraged to contact the firm for a confidential consultation.
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has launched an investigation into potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (NASDAQ: ERAS). The investigation aims to determine if the company's leadership fulfilled its obligations to shareholders and whether legal remedies are appropriate. Shareholders who purchased Erasca shares before January 14, 2025, are encouraged to contact the firm for a confidential consultation.
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 81,900 shares of Erasca, Inc. (NASDAQ:ERAS) valued at approximately $1.5 million during the second quarter. Other institutional investors have also adjusted their holdings in Erasca, which currently has 67.78% institutional ownership. Despite missing EPS estimates in its latest quarterly report, the company maintains a "Moderate Buy" consensus rating among analysts with an average price target of $22.09.
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Erasca, Inc. (ERAS) after the company disclosed receiving a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to Erasca's ERAS-0015. Following this news, Erasca's stock price dropped significantly. The law firm is encouraging affected investors to contact them to learn more about the investigation.
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)?
Erasca, Inc. recently reported wider net losses, filed a significant ESOP-related shelf registration, and is facing a securities class action lawsuit concerning its ERAS-0015 program. Despite these challenges, the company appointed a veteran oncologist-executive to lead R&D, aiming to strengthen its scientific oversight. The article examines how these developments, particularly the legal dispute, affect Erasca's investment narrative and highlight the varying analyst expectations for its stock.
Stifel reiterates Buy rating on Erasca stock, $30 target
Stifel has reiterated a Buy rating and a $30.00 price target on Erasca Inc. (NASDAQ: ERAS), despite the stock's significant surge over the past year and indications of potential overvaluation according to InvestingPro data. The company plans to advance its pan-RAS inhibitor ERAS-0015 into three registration-enabling studies starting in 2027, targeting non-small cell lung cancer and pancreatic ductal adenocarcinoma. This decision follows positive clinical trial updates and a successful public offering that raised approximately $632.5 million, contributing to increased analyst confidence and revised price targets from other firms.
Stifel reiterates Buy rating on Erasca stock, $30 target
Stifel reiterated a Buy rating and $30 price target for Erasca (NASDAQ:ERAS) due to the company's planned registration-enabling studies for its pan-RAS inhibitor ERAS-0015 in 2027. Erasca also recently reported promising second-quarter 2026 results, including a 57% unconfirmed overall response rate in pancreatic cancer patients and a successful public offering raising $632.5 million. Other analysts like Guggenheim, H.C. Wainwright, and Jefferies have also raised their price targets for Erasca, reflecting growing confidence in its oncology pipeline.
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)?
Erasca, Inc. recently reported wider net losses, filed a significant ESOP-related shelf registration, and is facing a securities class action lawsuit concerning its ERAS-0015 program, though it has also appointed a new president of R&D. These developments introduce both scientific leadership strength and increased legal/financial uncertainty, impacting the investment narrative for ERAS-0015. The article highlights the divergence in fair value estimates for Erasca's stock, reflecting differing views on how these challenges will affect the company's future.
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes
Erasca, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) detailing updated insider ownership. Jonathan E. Lim beneficially owns 10.4% of the common stock, while Conyee T. Lim holds a 5.6% beneficial stake. These figures are based on 349,762,035 shares outstanding as of August 4, 2026.
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages
Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.91. Despite a recent 3.9% decline in shares and missing analyst expectations for its quarterly loss, institutional investors hold a significant 67.78% of the stock. Several research firms have recently updated their price targets and ratings for Erasca.
Guggenheim raises Erasca stock price target to $21 on pipeline progress
Guggenheim has increased its price target for Erasca Inc. (NASDAQ: ERAS) to $21 from $20, maintaining a Buy rating, citing confidence in the company's RAS inhibitor pipeline progress. This follows Erasca's second-quarter 2026 results and a pipeline update, including advanced development plans for ERAS-0015 in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and a collaboration with Merck. Other analysts like H.C. Wainwright and Jefferies have also raised their price targets for Erasca, highlighting strong trial data and the potential of its drug candidates.
Guggenheim raises Erasca stock price target to $21 on pipeline progress
Guggenheim raised its price target for Erasca Inc (NASDAQ:ERAS) to $21 from $20, maintaining a Buy rating, citing progress in the company's RAS inhibitor pipeline, particularly the ERAS-0015 program. This follows Erasca's second-quarter results, a $500 million equity raise, and a new clinical collaboration with Merck. Other analysts like H.C. Wainwright and Jefferies have also increased their price targets due to promising trial data and the drug's potential.
ERAS: ERAS-0015 delivers strong efficacy and safety in RAS-mutant cancers, advancing toward pivotal trials
ERAS-0015 is showing strong efficacy and safety in treating RAS-mutant cancers, including NSCLC and PDAC, with high response rates. The company has a robust pipeline targeting RAS/MAPK-driven cancers and strong financial backing to support upcoming pivotal trials. This positions ERAS as a potential leader in the competitive RAS-targeting oncology market.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, stemming from misleading statements regarding its Preclinical data on ERAS-0015. Investors who purchased shares between January 14, 2025, and April 26, 2026, are encouraged to contact SBS to discuss their rights and the opportunity to become a lead plaintiff, with a deadline of August 10, 2026. The lawsuit claims that Erasca's public statements were false and materially misleading, causing investor damages when the truth emerged.
Erasca appoints Charles Fuchs as R&D president
Erasca Inc. (NASDAQ:ERAS) has appointed Charles S. Fuchs, M.D., M.P.H., as its new president of research and development. Dr. Fuchs brings over 30 years of oncology experience, including leadership roles at Genentech and Roche, where he oversaw the development of several approved therapies. Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP is reminding Erasca (NASDAQ: ERAS) investors of the August 10, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Erasca made misleading statements regarding its ERAS-0015 drug candidate's preclinical data, which was based on improper comparisons and led to patent infringement claims and a patient death during clinical trials. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, and suffered losses, may be eligible to participate.
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
Erasca, Inc., a clinical-stage precision oncology company, has appointed Charles S. Fuchs, M.D., M.P.H., as its new President of Research and Development. Dr. Fuchs brings over thirty years of leadership experience in oncology, including significant roles in drug development at Genentech/Roche and as director of the Yale Cancer Center. His appointment aims to strengthen Erasca's R&D strategy, particularly in advancing its RAS-targeting franchise for treating RAS/MAPK pathway-driven cancers.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP is reminding investors of the August 10, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit against Erasca, Inc. (ERAS). The lawsuit alleges that Erasca and its executives violated federal securities laws by making false or misleading statements regarding the ERAS-007 drug candidate, particularly concerning its preclinical data comparisons and potential patent infringement risks. Investors who purchased ERAS securities between January 13, 2023, and April 26, 2026, and suffered losses are encouraged to contact the firm.
Charles Fuchs Brings More Than 3 Decades in Oncology to Erasca
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has appointed Charles S. Fuchs, M.D., M.P.H., as president of research and development. Dr. Fuchs brings over three decades of oncology leadership and expertise in drug development, scientific innovation, and patient care, with a focus on gastrointestinal cancers. His experience is expected to shape Erasca's R&D strategy as the company expands development and prepares for the potential commercialization of its RAS-targeting franchise, aiming to address unmet needs in RAS/MAPK pathway-driven cancers.
Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Seek Leadership in a Securities Fraud Lawsuit by August 10, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding its drug ERAS-0015, which was accused by Revolution Medicines, Inc. of patent infringement and trade secret misappropriation. Investors who suffered losses and wish to serve as lead plaintiff must do so by August 10, 2026.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Hagens Berman is investigating a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims Erasca misled investors about its oncology candidate, ERAS-0015, regarding its competitive advantage, safety, and intellectual property, leading to a significant stock decline after disclosures of patent infringement allegations and a patient death. Investors who suffered losses and purchased stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to apply for lead plaintiff.
California State Teachers Retirement System Grows Position in Erasca, Inc. $ERAS
The California State Teachers Retirement System significantly increased its stake in Erasca, Inc. (NASDAQ:ERAS) by 1,812.7% in the first quarter of 2026, bringing its total holdings to 204,449 shares valued at $3.3 million. Despite facing investor lawsuits alleging misleading disclosures about its lead cancer drug candidate, ERAS-0015, the company maintains a "Moderate Buy" consensus rating from
